Himalaya Nutravedics India reported stellar FY26 results with a 105% surge in revenue to Rs 43.07 crore and a 231% jump in PAT to Rs 7.39 crore. The company successfully pivoted its business model, with own-brand products now accounting for over 51% of total revenue. While top-line and margin growth remains impressive, investors should note the widening negative operating cash flow and rising inventory levels as the company scales its D2C operations and marketing footprint.
Himalaya Nutravedics FY26 Performance: Revenue Rises 105%, PAT Jumps 231%
Revenue reached Rs 43.07 crore in FY26 compared to Rs 20.99 crore in FY25.
Profit After Tax surged to Rs 7.39 crore, up from Rs 2.23 crore in the previous year.
Reader Takeaway: Strong brand-led margin expansion is being offset by working capital pressure and negative operating cash flows.
What just happened
Himalaya Nutravedics India Limited reported a strong financial year, characterized by a fundamental shift in business composition. The company saw its revenue more than double YoY, while EBITDA margins expanded by 458 bps to reach 18.8%. This growth was primarily driven by the 'Own Brand Business' segment, which now contributes 51.1% of revenue, successfully reducing reliance on third-party contract manufacturing.
Why this matters
The pivot to own-brand products is delivering higher profitability, reflected in the 653 bps expansion in PAT margins. With a presence in over 17 states and a concentrated anchor market in Kerala, the company is now channeling Rs 7.5 crore into digital marketing and branding to accelerate its D2C segment.
Risks to watch
Despite high profitability, operating cash flow turned increasingly negative at Rs 3.83 crore, compared to Rs 1.39 crore in FY25. Inventory levels have ballooned to Rs 8.91 crore from Rs 3.28 crore, and trade receivables have also climbed, suggesting that the company is tying up a significant portion of its capital in working capital cycles as it scales.
Context metrics
Manufacturing is centered at a single WHO-GMP/ISO facility in Hyderabad, which is currently operating at 90.2% capacity for medicated oils. The company's EPS stands at Rs 18.3, signaling robust earnings per share growth for shareholders.
What to track next
Watch for improvement in cash conversion cycles. The management’s ability to stabilize operating cash flows while maintaining the current momentum in D2C customer acquisition will be the defining factor for the stock's valuation in the coming quarters.